Abstract
Introduction
Governments in the world' s largest pharmaceutical markets clearly have an
interest in promoting access to innovative medicines, but the relatively high
price of many novel drugs can place a heavy fi nancial burden on overtaxed
health care systems. Thus, the essential challenge for governments and other
payers is to strike a balance between the benefi ts and costs of making
innovative medicines more widely available.
Get the Answers You Need to Shape Your Strategy
- The European Commission wants to balance strict price controls and free
market pricing. What initiatives has the EU undertaken to achieve this
balance? Which EU markets have the strictest constraints on pharmaceutical
pricing? Are new policies likely to improve or worsen the climate for
pharmaceutical companies?
- Recently, the Japanese government has taken action intended to make
premiums for innovation more generous and more attainable. What price reforms
has the government made? Are they likely to in fact encourage innovation? Will
the new price premiums be achievable?
- In the United States, the increasing focus on drug prices will prompt more
payers to adopt evidence-based formularies. How is formulary decision making
evolving in the private sector? How is Medicare now encouraging health
economic research?
Scope
- EU innovation initiatives: a review of recent initiatives by the EU in
support of innovative medicines in Europe.
- Outlook and implications for the pharmaceutical industry: the future of
reimbursement for innovative drugs in the EU, Japan, and the United States.
- Detailed analysis of pricing and reimbursement in the major markets: an
examination of how health care payers in seven leading pharmaceutical markets
(France, Germany, Italy, Spain, United Kingdom, Japan, and United States)
approach the pricing and reimbursement of innovative drugs.
| 
View Cart
